Publication

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Chen, R
; 
Zinzani, PL
; 
Lee, HJ
; 
Armand, P
; 
Johnson, NA
; 
Brice, P
; ; 
Ribrag, V
; 
Molin, D
; 
Vassilakopoulos, TP
... show 8 more
Citations
Altmetric:
Abstract
Authors
Chen, R
Zinzani, PL
Lee, HJ
Armand, P
Johnson, NA
Brice, P
Radford, John A
Ribrag, V
Molin, D
Vassilakopoulos, TP
Tomita, A
von, Tresckow B
Shipp, MA
Lin, JX
Kim, E
Nahar, A
Balakumaran, A
Moskowitz, CH
Affiliation
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
Description
Date
2019
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144-53.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/622416
Embedded videos